Skip to main content

Neurogene Inc.

NGNE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001404644

No open-market purchases or sales by Neurogene Inc. insiders were filed in the last 90 days; 111 institutions reported holding it in 13F filings for Q2 2026, worth $544.4M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Neurogene Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of NGNE: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders6452−12
Shares20.8M18.7M−2.08M (−10.0%)
Value$21.4M$12.0M−$9.44M (−44.1%)

New holders (5)

Institutions that held Neurogene Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to NGNE in Q3 2022
InstitutionSharesValue% of portfolio
Privium Fund Management (UK) Ltd117,200$75.0K0.10%
Bridgeway Capital Management, LLC83,800$54.0K0.00%
Acadian Asset Management LLC21,188$13.0K0.00%
Endurance Wealth Management, Inc.10,000$6.00K0.00%
China Universal Asset Management Co., Ltd.399$00.00%

Sold out (17)

Institutions that held Neurogene Inc. at the end of Q2 2022 and filed for Q3 2022 without it.